Revenues and EBITDA growth in line with FY 2025 Guidance. Proposed ordinary dividend per share of €1.30, +8.3% vs 2024

Revenues and EBITDA growth in line with FY 2025 Guidance Proposed ordinary dividend per share of €1.30, +8.3% vs 2024 2026 Guidance at CER: Revenue growth between +5% and +6% and Adjusted EBITDA Margin at 32%-33%

• REVENUES: € 1,195 MILLION, +4% AT CER VS. 2024 (+1% AT CURRENT EXCHANGE RATES, NEGATIVE FX IMPACT OF € 34 MILLION), +5%

  excluding COVID, in line with FY 2025 Guidance

• ADJUSTED1 EBITDA2: € 394 MILLION, +4% AT CER VS. 2024 (IN LINE AT CURRENT EXCHANGE RATES, NEGATIVE FX IMPACT OF € 15

  MILLION), WITH A MARGIN OF 33% AT BOTH CURRENT AND CONSTANT EXCHANGE RATES AND IN LINE WITH THE GUIDANCE

• GUIDANCE 2026 AT CER: REVENUE GROWTH BETWEEN +5% AND +6% AND ADJUSTED EBITDA MARGIN AT 32%-33%

• SHARE BUYBACK PROGRAM AIMED AT REMUNERATING SHAREHOLDERS LAUNCHED

  Saluggia (Italy), March 20, 2026 - The Board of Directors of Diasorin S.p.A. (FTSE MIB: DIA):

• examined and approved the Group's Consolidated Financial Statements as of December 31, 2025;

• examined and approved the Company's Draft Separate Financial Statements at December 31, 2025;

• approved the proposal to distribute an ordinary dividend of €1.30 per share, gross of withholding taxes, excluding treasury shares, with ex-dividend date on 18 May 2026, record date on 19 May 2026 and payment date on 20 May 2026; in light of the purchases that are planned and may be carried out pursuant to the share buyback program authorised by the shareholders' meeting of 27 January 2026, and of any treasury shares that may be cancelled pursuant to the shareholders' resolution adopted on the same date, the total amount of the dividend will be determined based on the number of shares outstanding as of the ex-dividend date and the number of treasury shares effectively held by the Company as of the record date. Taking into account the treasury shares held up to and including 19 March 2026, the maximum total amount of the dividend is equal to € 66,507,838.80;

• examined and approved the management report, including the Sustainability Reporting pursuant to the Legislative Decree no. 125/2024;

• approved the Corporate Governance Report as of December 31, 2025;

• approved the Report on the remuneration policy and fees paid pursuant to Art. 123-ter of Legislative Decree no. 58/1998;

• resolved to propose to the next Shareholders' Meeting the establishment of a new stock option plan pursuant to Art. 114-bis of Legislative Decree no. 58/1998;

• evaluated and confirmed the continued compliance with the legal requirements of its Independent Directors according to the Corporate Governance Code;

• acknowledged of the self-evaluation process carried out by the Board of Statutory Auditors and its outcomes, with particular reference to the compliance with the independence requirement as set out by current regulations for each of its members;

• resolved to call an Ordinary Shareholders' Meeting on April 29, 2026, on a single calling.

The Board of Directors, having obtained the favorable opinion of the Board of Statutory Auditors and verified that the requirements set forth in the By-laws are met, also resolved to appoint, with effect from April 1, 2026, Teresa Cervino as the new Officer in charge of preparing the Company's financial and sustainability reports pursuant to Article 154-bis of Legislative Decree No. 58/1998.

1With reference to the indicators Adjusted Gross Margin, Adjusted EBITDA, Adjusted EBIT, and Adjusted Net Income, please refer to the table at the end of this Press Release.

2EBITDA is defined as the "Operating Result", gross of amortization and depreciation of intangible and tangible assets. EBITDA is a measure used by the Company to monitor and evaluate the Group's operating performance and is not defined as an accounting measure in IFRS and therefore shall not be considered an alternative measure for assessing the Group's operating result performance. Since the composition of EBITDA is not regulated by the reference accounting standards, the criterion of determination applied by the Group may not be homogeneous

ith that adopted by other operators and/or groups and therefore may not be comparable.

TABLES OF RESULTS1

Diasorin Group

Diasorin S.p.A.

Comments on Economic Results

REVENUES: € 1,195 million, +4% at CER compared to 2024 (+1% at current exchange rates, with a negative FX impact of € 34 million). Excluding the COVID business, revenues grew by 5% at CER and were therefore in line with FY 2025 guidance.

The revenue performance by business line was as follows:

• Ex -COVID immunodiagnostics: € 821 million, +7% at CER compared to 2024 (+5% at current exchange rates, with a negative FX impact of € 19 million), with an increase of € 37 million, driven by the strong performance of CLIA specialty test sales, which more than offset the contraction in revenues from the Chinese market, mainly attributable to the implementation of Volume-Based Procurement (VBP) regulation, which is impacting the performance of all companies operating in the diagnostics sector. Excluding the contribution of the Chinese market, business growth amounted to

  +8% at CER (+6% at current exchange rates).

  The success of this business line was also confirmed in Q4'25, recording growth of +6% at CER (+2% at current exchange rates), in line with the positive trend seen in previous quarters, driven by the hospital strategy implemented in the United States-continuing toward the target of reaching 600 facilities by 2027-as well as by increased sales in the European market. Excluding the contribution of the Chinese market, Q4'25 growth amounted to +7% at CER (+3% at current exchange rates).

• Ex-COVID molecular diagnostics: € 196 million, in line at CER compared to 2024 (-4% at current exchange rates, with a

  negative FX impact of € 8 million), driven by the following factors:

  • increase in sales of test panels on automated multiplexing platforms (VERIGENE I and LIAISON PLEX);

  • decline in sales of respiratory panels on the LIAISON MDX low-plex platform and on non-automated multiplexing

    platforms;

  • discontinuation of the ARIES platform.

    The performance in Q4'25, compared with the same period in 2024 (-5% at CER; -12% at current exchange rates), was mainly impacted by the late start of the flu season, with a consequent effect on respiratory panel sales.

• Licensed Technologies: € 165 million, in line at CER compared to 2024 (-4% at current exchange rates, with a negative FX impact of € 7 million), driven by the strong performance of customers in the Diagnostics segment, partially offset by a decline in sales from Life Science customers, which were negatively impacted in the United States by policies reducing NIH funding and the resulting overall contraction in research spending.

  Q4'25 (-11% at CER; -19% at current exchange rates) was affected by the unfavorable timing of certain key orders that had positively supported revenues in the first months of 2025.

• COVID: € 13 million, -49% at CER (-52% at current exchange rates, with an FX impact of approximately € 1 million), declining as expected compared to 2024.

  The revenue performance by geographic area, excluding the contribution of COVID products, was as follows:

• North America Direct: € 584 million, +7% at CER compared to 2024 (+3% at current exchange rates, with a negative FX

  impact of € 26 million).

  The increase in sales was mainly driven by the strong performance of the immunodiagnostics business (+15% at CER and +10% at current exchange rates), confirming the success of the hospital strategy and the contribution of the broad CLIA specialty test offering.

  Positive performance was also recorded for specialty (so-called targeted) tests on the LIAISON MDX low-plex molecular platform, which offset, on the one hand, the overall weakening of the respiratory segment due to limited test volumes associated with the late start of the flu season and, on the other hand, the unfavorable comparison with 2024 following the discontinuation of the ARIES low-plex molecular platform.

• Europe Direct: € 424 million, +4% at both constant and current exchange rates compared to 2024.

  Growth was mainly driven by the solid performance of the immunodiagnostics business, particularly specialty tests that characterize Diasorin's offering, despite an unfavorable comparison with 2024, which had benefited from volume increases driven by infectious disease outbreaks in major European countries; excluding this effect, growth was approximately +6% at CER.

• Rest of the World: € 175 million, in line at CER (-4% at current exchange rates, with a negative FX impact of € 7 million).

  The positive performance in countries where Diasorin operates either directly or through local distributors was offset by the contraction of revenues in the Chinese market, mainly attributable to the implementation of Volume-Based Procurement (VBP) regulation, which is impacting the performance of all companies operating in the diagnostics sector. Excluding China, the "Rest of the World" area recorded growth of +5% at CER.

  ADJUSTED1 GROSS PROFIT: € 778 million, +2% at CER compared to 2024 (-1% at current exchange rates, with a negative FX

  impact of € 23 million), with an incidence on revenues of 65% at both constant and current exchange rates.

  ADJUSTED1 EBITDA2: € 394 million, +4% at CER compared to 2024 (in line at current exchange rates, with a negative FX impact of € 15 million), with an incidence on revenues of 33% at both constant and current exchange rates, in line with the performance recorded in previous quarters and with FY 2025 guidance.

  ADJUSTED1 EBIT: € 304 million, +4% at CER compared to 2024 (in line at current exchange rates, with a negative FX impact of

  € 13 million), with an incidence on revenues of 25%.

  ADJUSTED1 NET FINANCIAL CHARGES: € 1 million (€ 4 million in financial income in 2024). The € 5 million difference is attributable to lower interest income earned on cash, due to the combined effect of declining interest rates and the related investment strategy.

  TAXES: € 62 million, with a tax rate of 29%. This figure includes the impact of non-recurring tax charges, mainly related to extraordinary dividends distributed by subsidiaries during the year and estimated non-cash costs associated with the reorganization of operating activities at the Chinese subsidiary. Excluding these effects, the Group's tax rate stands at 25%.

  ADJUSTED1 NET PROFIT: € 223 million (with an incidence on revenues of 19%), down by € 13 million (-6%) compared to 2024, as a result of an unfavorable foreign exchange effect, higher adjusted net financial charges, and higher income taxes for the period.

  Comment on Financial Results

  CONSOLIDATED NET FINANCIAL DEBT: -€ 580 million (-€ 618 million as of December 31, 2024). The € 38 million change mainly reflects solid operating cash generation, partially offset by dividend payments of € 63 million and a € 97 million outlay following the exercise of withdrawal rights by certain shareholders as a result of the enhanced voting mechanism. FREE CASH FLOW3: € 209 million as of December 31, 2025 (€ 241 million as of December 31, 2024).

  The change compared to the previous year is attributable, in addition to the negative foreign exchange impact, to higher taxes paid, mainly in Italy following the expiration of the Patent Box tax credit, and in the United States, which in the prior year had benefited from the use of carryforward tax credits. In addition, following the conversion into law of Legislative Decree No. 95 of June 30, 2025 (the so-called "Economy Decree"), an amount of approximately € 6 million was paid in Italy as a payback related to the years 2015-2018.

  Business Highlights Immunodiagnostics:

• De Novo authorization for the first fully automated test for the diagnosis of the hepatitis delta virus (HDV) in the United

  States;

• Introduction, in partnership with QIAGEN, in countries accepting the CE mark, of the new generation of the LIAISON

  QuantiFERON-TB Gold Plus II test, which ensures faster execution and higher throughput;

• New evidence presented at ACEP 2025 on the role of MeMed BV in supporting clinical decision-making in emergency medicine;

• Launch of LIAISON TSH-R Ab, a test designed to improve the diagnosis of Graves' disease, in all CE-mark accepting countries.

  Molecular Diagnostics: Point-of-Care

• FDA 510(k) clearance and CLIA-waiver for the LIAISON NES Molecular Diagnostics Point-of-Care platform and its first assay, the 4-Plex Respiratory Panel (COVID-19, Flu A/B & RSV);

• Submission of the LIAISON NES Group A Strep molecular test to the U.S. FDA for 510(k) Clearance and CLIA Waiver;

• Signing of an exclusive distribution agreement for the U.S. hospital channel with Fisher Scientific, part of Thermo Fisher Scientific, and for the Physician Office Laboratories (POLs) channel with McKesson Medical Surgical, in support of the market-access strategy for the LIAISON NES platform.

  Multiplexing

• Launch of the full panel portfolio to diagnose bloodstream infections on LIAISON PLEX, the new multiplexing platform of the Group, following the U.S. FDA 510(k) clearance for the LIAISON PLEX Gram-Positive Blood Culture Assay, LIAISON PLEX Gram-Negative Blood Culture Assay, and LIAISON PLEX Blood Culture Yeast Assay;

• Submission to the U.S. FDA of the 510(k) clearance application for the LIAISON PLEX Gastrointestinal Flex Assay;

• Commercial agreement with Quest Diagnostics for the use of the innovative LIAISON PLEX multiplexing molecular platform.

  Low-Plex

• FDA 510(k) clearance for the SIMPLEXA COVID-19, Flu A/B & RSV Direct test on the LIAISON MDX platform;

• Launch of a new Measles Virus Primer Pair in the U.S., expanding the growing portfolio of Analyte-Specific Reagents (ASRs);

• Launch of Simplexa C. auris direct assay on the LIAISON MDX platform for all countries accepting the CE Mark.

3Free Cash Flo equals net cash flo

generated from operating activities including uses for investment and before payment of interest and acquisitions of companies and businesses.

Other key events

Launch of the share buyback program aimed at shareholder remuneration

Within the authorization approved by the Shareholders' Meeting held on January 27, 2026, the Board of Directors, meeting on the same date, resolved to launch a share buyback program aimed at remunerating shareholders, for a total outlay of up to € 250,000,000 and for a maximum of 4,500,000 ordinary shares, representing 8.04% of the share capital. The Company has repurchased 1,840,791 treasury shares, equal to 3.29% of the share capital as of the date of the shareholders' authorization and holds a total number of treasury shares equal to 4,788,381 (representing 8.56% of the share capital), taking into account the purchases carried out up to and including 19 March 2026.

Reorganization of operating activities at the chinese subsidiary

In Q4'25, Diasorin launched a project aimed at reorganizing operating activities at its Chinese subsidiary, in continuity with the path already undertaken through similar initiatives and as part of its strategy to optimize production sites globally, with the objective of strengthening long-term competitiveness.

The sustainability analysis of the Chinese plant, carried out in light of the new macroeconomic conditions and the

introduction of the Volume-Based Procurement (VBP) regulation, led to the adoption of this decision.

The transaction, which is expected to be completed by the end of 2026, will be implemented in compliance with existing contractual agreements and is expected to generate operating synergies and annual cost savings estimated at approximately € 6 million, with a cash payback period of less than one year. This will allow the Group to focus its commercial strategy on specialty tests, such as latent tuberculosis tests and the immunodiagnostics panel for gastrointestinal infections.

The implementation of the project entails total non-recurring costs, almost entirely non-cash in nature, of up to € 22 million, of which approximately € 20 million have already been recognized in the consolidated financial statements for the year 2025.